 Puma Biotechnology continues to report encouraging clinical data for its flagship product, NERLYNX. Unfortunately, the commercial numbers continue to remain in purgatory. I take a look at the companys recent earnings report to extract some key commercial metrics and trends that have developed over 2020. 